The IRMA Community
Newsletters
Research IRM
Click a keyword to search titles using our InfoSci-OnDemand powered search:
|
Drug Delivery Strategies for Tolerogenic Therapy for Autoimmune Diseases in an Antigen-Specific Manner
|
|
Author(s): Kevin J. Peine (The University of North Carolina at Chapel Hill, USA), Naihan Chen (The University of North Carolina at Chapel Hill, USA), Eric M. Bachelder (The University of North Carolina at Chapel Hill, USA)and Kristy M. Ainslie (The University of North Carolina at Chapel Hill, USA)
Copyright: 2017
Pages: 29
Source title:
Recent Advances in Drug Delivery Technology
Source Author(s)/Editor(s): Raj K. Keservani (Rajiv Gandhi Proudyogiki Vishwavidyalaya, India), Anil K. Sharma (GD Goenka University, India)and Rajesh Kumar Kesharwani (National Institute of Technology, Warangal, India)
DOI: 10.4018/978-1-5225-0754-3.ch002
Purchase
|
Abstract
Autoimmune diseases are the result of an improper immune response towards a self-antigen. Predominantly, autoimmune diseases have been treated using therapies that suppress systemic immune responses, which can result in significant side-effects like increased risk of infection and cancer. Alternatively, induction of immune tolerance through antigen-specific therapies can inhibit disease-associated responses without systemic suppression. Previously, immune tolerance has been accomplished by soluble antigen delivery through oral, nasal or sublingual routes. However, these therapies have shown minimal success in clinical settings. In an attempt to increase the efficacy of these therapies, recent work has utilized microparticulate delivery vehicles for the induction of immune tolerance. Microparticles are capable of increasing the solubility and circulation of cargo. In addition, their ability to passively target macrophages and dendritic cells increases their capacity for modulating the immune response. Recent work has shown microparticles fabricated with disease-associated antigens have limited disease progression and severity in animal models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis. Inhibition of disease progression has corresponded with an antigen-specific decrease in inflammatory responses. The emerging field of inducing tolerance through microparticle-based therapies can limit therapeutic side-effects and increase patient quality of life by providing for long-term suppression of autoimmune disorders without compromising systemic immune function.
Related Content
|
Abul Kalam Azad, Mohamad Dayoob, Fatema Tuz Zohera.
© 2024.
21 pages.
|
|
W. H. P. A. D. Perera, Mithuni N. Senadeera, Dinusha N. Udukala.
© 2024.
26 pages.
|
|
Thi Van Anh Nguyen, Trang Nguyen Ngoc, Thanh Tung Bui.
© 2024.
43 pages.
|
|
Abul Kalam Azad, Mallari Praveen, Wan Mohd Azizi Bin Wan Sulaiman.
© 2024.
31 pages.
|
|
Bancha Yingngam.
© 2024.
43 pages.
|
|
Babi Lakkoju, Swapna Asuthkar, Gundla Rambabu, Kolli Balakrishna.
© 2024.
20 pages.
|
|
Arthi Gunasekaran, Trisha Sathya, Vijaya Anand Arumugam, Balamuralikrishnan Balasubramanian, Asirvatham Alwin Robert, Arun Meyyazhagan.
© 2024.
31 pages.
|
|
|